The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide, used in Diabetes Mellitus Type 2, has shown promising results for motor symptoms in PD clinical trials [20]. This evidence concerns the gene GCG and type 2 diabetes mellitus.